Abstract
Historically, the transfemoral approach (TFA) was the primary access site for percutaneous coronary procedures. Over the past decade, the transradial approach (TRA) has gained significant popularity. As TRA usage has increased, its advantages over TFA have become increasingly clear. This paper presents a systematic literature search comparing the benefits and risks of both approaches. From an initial 140 citations, 38 studies met the eligibility criteria for this review.
Introduction
For decades, the femoral artery in the groin served as the standard "highway" for percutaneous coronary intervention (PCI). While effective, TFA is associated with significant risks of major bleeding and vascular complications, particularly when aggressive anticoagulation is required. The transradial approach (TRA), utilizing the smaller radial artery in the wrist, has emerged as a safer alternative. This review synthesizes data from major clinical trials to evaluate whether the safety and recovery benefits of TRA outweigh technical challenges such as procedural complexity and the associated learning curve.
Methods
A systematic review was conducted across databases including Medline, Embase, and the Cochrane Library. The authors screened 140 citations, ultimately selecting 38 high-quality studies, including randomized controlled trials (RCTs), meta-analyses, and large-scale retrospective cohorts. Key data sources included the RIVAL and MATRIX trials, the RIFLE-STEACS trial, and various large clinical registries.
Clinical Evidence and Safety
The most consistent finding across the reviewed literature is a dramatic reduction in vascular-access complications. The RIVAL study demonstrated a 60% reduction in such complications for TRA, while the MATRIX trial reported a 63% reduction. These benefits are particularly pronounced in female patients and those presenting with ST-elevation myocardial infarction (STEMI). For instance, the RIFLE-STEACS trial found a 47% reduction in access-site related bleeding and a significant decrease in cardiac mortality among STEMI patients.
Furthermore, Romagnoli et al. observed that 30-day Major Adverse Cardiac Events (MACE) were significantly lower in the TRA group (13.6%) compared to the TFA group (21.0%).
Economic and Quality of Life Considerations
Beyond clinical safety, TRA offers significant practical advantages. It allows for immediate ambulation, which shortens hospital stays and improves patient satisfaction. Economically, the "micro-costs" associated with TRA are lower; one analysis found the cost of therapeutic success was 3,060 EUR for TRA versus 3,374 EUR for TFA, largely due to reduced indirect costs and shorter recovery times.
Challenges and the Learning Curve
Despite its benefits, TRA adoption faces hurdles. There is a documented "learning curve": high-volume radial operators achieve shorter procedural times and lower radiation exposure than novices. During the learning phase, TRA may lead to higher fluoroscopy times and increased radiation exposure for both patients and clinicians. Additionally, TRA has a higher "cross-over" rate, where anatomical variations or small vessel size necessitate a mid-procedure switch to the femoral site.
Conclusion
The transradial approach represents a significant advancement in interventional cardiology, offering superior safety profiles and cost-effectiveness compared to the traditional transfemoral approach. While TFA remains necessary for complex cases requiring large-bore equipment, TRA is increasingly becoming the preferred standard for routine percutaneous coronary procedures, provided operators receive adequate training to overcome the initial learning curve.
Summary updated